Education
About Us
Working with TipRanks
Follow Us
Sensei Biotherapeutics (SNSE)
NASDAQ:SNSE
SNSE Stock Chart & Stats
$9.38
-$0.03(-5.03%)
At close: 4:00 PM EST
$9.38
-$0.03(-5.03%)
Day’s Range― - ―
52-Week Range$5.00 - $18.35
Previous CloseN/A
Volume8.76M
Average Volume (3M)38.93K
Market Cap
$13.90M
Enterprise Value-$15.25M
Total Cash (Recent Filing)$28.63M
Total Debt (Recent Filing)$2.56M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Nov 11, 2025EPS Estimate
-3.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.91
Shares Outstanding1,261,290
10 Day Avg. Volume109,584
30 Day Avg. Volume38,927
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-1.10
Enterprise Value/Revenue-28.03
Enterprise Value/Gross Profit-149.52
Enterprise Value/Ebitda0.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe higher 15 mg/kg dose of solnerstotug showed clinical responses, especially in patients with PD-L1 resistant tumors.
Clinical TrialsSolnerstotug demonstrated safety and a promising progression-free survival rate in a challenging post-CKI setting.
Future DevelopmentTwo planned Phase 2 trials are expected, focusing on patients who have failed anti-PD-L1 treatment, indicating ongoing development and potential future advancements.
Bears Say
Financial PerformanceSensei announced 2Q25 financial results, posting EPS of ($3.91) compared to our estimate of ($0.31).
Sensei Biotherapeutics News
SNSE FAQ
What was Sensei Biotherapeutics’s price range in the past 12 months?
Sensei Biotherapeutics lowest stock price was $5.00 and its highest was $18.35 in the past 12 months.
What is Sensei Biotherapeutics’s market cap?
Sensei Biotherapeutics’s market cap is $13.90M.
When is Sensei Biotherapeutics’s upcoming earnings report date?
Sensei Biotherapeutics’s upcoming earnings report date is Nov 11, 2025 which is in 11 days.
How were Sensei Biotherapeutics’s earnings last quarter?
Sensei Biotherapeutics released its earnings results on Aug 05, 2025. The company reported -$3.91 earnings per share for the quarter, beating the consensus estimate of -$5.6 by $1.69.
Is Sensei Biotherapeutics overvalued?
According to Wall Street analysts Sensei Biotherapeutics’s price is currently Overvalued.
Does Sensei Biotherapeutics pay dividends?
Sensei Biotherapeutics does not currently pay dividends.
What is Sensei Biotherapeutics’s EPS estimate?
Sensei Biotherapeutics’s EPS estimate is -3.73.
How many shares outstanding does Sensei Biotherapeutics have?
Sensei Biotherapeutics has 1,261,290 shares outstanding.
What happened to Sensei Biotherapeutics’s price movement after its last earnings report?
Sensei Biotherapeutics reported an EPS of -$3.91 in its last earnings report, beating expectations of -$5.6. Following the earnings report the stock price went down -4.74%.
Which hedge fund is a major shareholder of Sensei Biotherapeutics?
Currently, no hedge funds are holding shares in SNSE
Company Description
Sensei Biotherapeutics
Sensei Biotherapeutics, Inc. (SNSE) is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immunotherapies for the treatment of cancer. The company operates in the biotechnology and pharmaceutical sectors, leveraging its innovative ImmunoPhage™ platform to develop a pipeline of novel therapies aimed at modulating the immune system to recognize and destroy cancer cells. Sensei's core product candidates are designed to target various types of cancer, offering potential new treatment options for patients with unmet medical needs.
SNSE Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Cellectar Biosciences
―
Cocrystal Pharma
―
BioRestorative Therapies
―
Athira Pharma
―
Bolt Biotherapeutics
―
Ownership Overview
31.23% Insiders
2.87% Mutual Funds
3.38% Other Institutional Investors
60.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---